Navigation Links
Cempra, Inc., Announces Notification of Patent Allowance for U.S. Patent Application on Taksta Loading Dose Formulation
Date:5/30/2013

CHAPEL HILL, N.C., May 30, 2013 /PRNewswire/ -- Cempra, Inc., (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,450,300 on May 28, 2013 with claims directed to the company's novel loading dose regimen for Taksta™.  The patent, entitled "Fusidic Acid Dosing Regimens for Treatment of Bacterial Infections," provides protection until 2029, excluding possible patent term extensions. 

"The issuance of this patent may add to the commercial value of Taksta as an important antibiotic candidate, currently in a Phase 2 clinical study in patients with prosthetic joint infections," said Prabhavathi Fernandes , Ph.D., chief executive officer of Cempra.  "Our now proprietary loading dose regimen for Taksta was a novel innovation designed so that the drug would rapidly reach therapeutic blood levels and minimize the risk of drug resistance. The patent provides protection in addition to the expected U.S. market exclusivity obtained through Waxman-Hatch, the GAIN Act, pediatric testing and, possibly, the Orphan Drug Act."

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases.  Cempra's two lead product candidates are currently in advanced clinical development.  Solithromycin (CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan.  Taksta™ (CEM-102) is Cempra's second product candidate currently in a Phase 2 clinical trial for prosthetic joint infections.  Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the results of studies of our product candidates conducted by others; the results, timing, costs and regulatory review of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our anticipated capital expenditures and our estimates regarding our capital requirements; our ability to obtain FDA approval of our product candidates; our dependence on the success of solithromycin and Taksta; and innovation by our competitors. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

Investor and Media Contacts:
Robert E. Flamm , Ph.D.
Russo Partners, LLC
(212) 845-4226 
Robert.flamm@russopartnersllc.com

Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com


'/>"/>
SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan
2. Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results
3. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
4. Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
5. Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
6. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
7. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
8. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
9. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
10. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
11. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... The innovator of COMBO ... s first dual therapy stent, introduces catheters for ... OrbusNeich, a global company specializing in the provision of ... products to treat peripheral artery disease. The JADE™ and ... for lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to ... patients on a global scale. Medical professionals from Europe ... and the US have already signed up for the app, ... totally secure environment. Education  "Imagine a doctor ... a surgeon at Harvard to treat a bomb victim via live ...
(Date:5/23/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the ... The hands-on learning experience is a 12-week summer program, ... Fellowship and Internship programs bring participants ... interns are provided optional housing free of charge through ... the Riverfront Residence Hall to foster communication and collaboration ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... 24, 2016 , ... Growing in popularity, more and more people continue to ... and easily accessible. Whether someone chooses to cut gluten out of their life for ... Kullen Grocery stocks their shelves with many different gluten-free products all year round. And ...
(Date:5/24/2016)... ... May 24, 2016 , ... Tuesday, May 24, Women's Excellence in ... enhanced with Young Living Essential Oils, taught by Patti Dolan, RYT, a Young ... location. Yoga Flow is 6:30pm - 7:15pm followed by a small intro to the ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Controlling and maintaining ... with the launch of the Aquanta Water Heater Controller , a first-of-its-kind system ... or web-enabled device. As the Nest thermostat does for HVAC systems, Aquanta gives ...
(Date:5/24/2016)... ... 2016 , ... Aloria Health Announces Opening of Eating Disorder ... Aloria Health, specializing in a re-imagined, client-oriented approach to the treatment of eating ... facility for outpatient, day treatment and residential care. Aloria Milwaukee will open its ...
(Date:5/24/2016)... ... May 24, 2016 , ... The old expression “a pain in ... common injury that’s often misunderstood, whiplash should be swiftly diagnosed and treated if those ... surgeon at Atlantic Spine Center . , So named because of the ...
Breaking Medicine News(10 mins):